Atypical antipsychotic drugs and long-term outcome in schizophrenia

摘要: Long-term outcomes for patients with schizophrenia have been disappointing. The article discusses how the typical antipsychotics (clozapine and risperidone) as well several agents that should be available in near future (olanzapine, sertindole, quetiapine, ziprasidone) might improve outcome then focuses on antipsychotic relapse rates newly released olanzapine. Considerable evidence shows compliant maintained atypical are substantially lower than those conventional antipsychotics. Also, decreased extrapyramidal symptom liability of newer medications will make it easier to prescribe more effective doses can maximize prevention without simultaneously interfering patient's quality life or motor functioning. authors describe clinical observations olanzapine based their 3 years experience using this agent a phase trial. They suggest like widely used, some problems associated long-term use diminish, but other issues concerns common. In particular: (1) Despite better side effect profiles, not solve noncompliance problem. A significant proportion still need depot therapy. (2) There arising from "awakenings" phenomena where become touch losses painful inner feelings. It seems likely rehabilitation services increased point they amenable psychiatric rehabilitation.